Skip to main content

Amgen

2022 Oncology Biosimilar Guide to Patient Support Services

Amgen Assist 360/FIRST STEP Program

Amgen Assist 360
888-427-7478
Amgen FIRST STEP
888-657-8371

Amgen offers assistance to patients through Amgen Assist 360, Amgen FIRST STEP, and the Amgen Safety Net Foundation. The complete list of oncology biosimilar medications from Amgen, including Kanjinti (trastuzumab-anns), Mvasi (bevacizumab-awwb), and Riabni (rituximab-arrx), is provided in the Table.

Amgen Assist 360

Amgen Assist 360 provides resources such as Amgen Reimbursement Counselors to conduct benefit verifications and Amgen Nurse Navigators who can help find resources that are most important to your patients. Please visit Amgen's website for more information. To enroll your patient in the Amgen Nurse Navigator program, download the enrollment form.

Amgen FIRST STEP

This program can help your eligible commercially insured patients cover their out-of-pocket prescriptions costs, including deductible, coinsurance, and copayment. Patients may be eligible if they:

  • Have been prescribed 1 or more qualifying Amgen products
  • Have private commercial health insurance that covers medication costs for the qualifying Amgen product(s)
  • Are not participating in any federal-, state-, or government-funded program such as Medicare, Medicare Advantage, Medicare Part D, Medicaid, Medigap, Veterans Affairs, the Department of Defense, or Tricare
  • Do not seek reimbursement for value received from the Amgen FIRST STEP program from any third-party payers, including flexible spending accounts or healthcare savings accounts.

Patients can register for this program by visiting AmgenFirstStep.com. For more information from an Amgen FIRST STEP representative, call 888-4ASSIST (888-427-7478).

Amgen Safety Net Foundation

This foundation assists patients who are uninsured or their insurance plan excludes the prescribed Amgen medicine or its generic/biosimilar. Patients may be eligible if they:

  • Have lived in the United States or its territories for 6 months or longer
  • Satisfy income eligibility requirements
  • Have Medicare Part D with product coverage but cannot afford their out-of-pocket costs.

To apply to the Amgen Safety Net Foundation, please visit our website, and select the prescribed medicine.

TABLE Amgen Biosimilar Oncology Drugs

Drugs
Indications
Patient support programs

Drug
Kanjinti (trastuzumab-anns)
Indications
Treatment of HER2-overexpressing breast cancer; treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma
Patient support programs

Drug
Mvasi (bevacizumab-awwb)
Indications
Patient support programs

Drug
Riabni (rituximab-arrx)
Indications
Patient support programs

NSCLC indicates non–small‑cell lung cancer.

Mvasi (bevacizumab-awwb) Indications

Treatment of recurrent glioblastoma; treatment of persistent, recurrent, or metastatic cervical cancer, in combination with chemotherapy; treatment of metastatic colorectal cancer, in combination with chemotherapy or after disease progression with a bevacizumab-containing regimen; treatment of unresectable, locally advanced, recurrent, or metastatic nonsquamous NSCLC, in combination with carboplatin and paclitaxel; treatment of metastatic renal-cell carcinoma, in combination with interferon-alfa

Riabni (rituximab-arrx) Indications

Treatment of adult patients with non-Hodgkin lymphoma (NHL), including relapsed or refractory, low-grade or follicular, CD20-positive B-cell NHL as a single agent; previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy; in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy; non-progressing, low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy; previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or other anthracycline-based chemotherapy regimens; treatment of adult patients with chronic lymphocytic leukemia (CLL), including previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide